 |
|
Melanoma Trial Results
1. Sentinel Node Biopsy Helps Some Melanoma Patients Live Longer
(Posted: 05/14/2005, Updated: 10/02/2006) - A technique called lymphatic mapping and sentinel-node biopsy - which looks for cancer in a few lymph nodes first - was better than a "watch and wait" approach in helping melanoma patients whose cancer had spread to the lymph nodes to live longer, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.
2. New Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma; Technique May Also Apply to Other Common Cancers
(Posted: 08/31/2006) - A team of researchers at NCI has demonstrated sustained regression of advanced melanoma in a study of 17 patients by genetically engineering patients' own white blood cells to recognize and attack cancer cells. The study appears in the online edition of the journal Science on August 31, 2006.
3. Response to Immunotherapy for Melanoma Tied to Autoimmunity
(Posted: 02/22/2006) - Patients treated for melanoma skin cancer with adjuvant interferon alfa-2b who developed clinical signs of autoimmunity were significantly more likely than those who did not to respond to the treatment, according to a report in the Feb. 16, 2006, issue of the New England Journal of Medicine.
4. NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
(Posted: 03/31/2005) - A team of researchers, led by Steven A. Rosenberg, M.D., at the National Cancer Institute, part of the National Institutes of Health, have found that patients with advanced melanoma who had not responded to previous therapies experienced a significant reduction in the size of their cancers as a result of receiving a new immunotherapy.
5. Researchers Shut Off Immune Cell Inhibition, Causing Tumor Shrinkage and Autoimmunity in Patients With Metastatic Melanoma
(Posted: 06/23/2003) - Scientists at the National Cancer Institute (NCI) have found a new method for modifying the immune system of cancer patients to induce cancer regression. Inhibiting a molecule known as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which has a critical role in regulating the immune response, can enable the immune system to attack some patients' tumors, the scientists report in the Proceedings of the National Academy of Sciences*.
1 2 Next >
|
|
|
